Reading FBLG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FBLG free→Reading FBLG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FBLG free→QuarterlyIQ Insights · FBLG
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. As previously disclosed, on May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into that certain At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell shares of its common stock, par value $0.00001 per share (the “Common Stock”) from time to time through or to the Sales Agent (the “ATM Offering”). The shares of Common Stock to be sold under the S…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 4, 2026 (the “Grant Date”), the Compensation Committee of the Board of Directors (the “Board”) of FibroBiologics, Inc. (the “Company”) granted, pursuant to the Company’s 2022 Stock Plan, options to purchase 92,410 shares of common stock to Pete O’Heeron, the Company’s’ Chief Executive Officer, and options to purchase 61,607 shares of common…
Entry into a Material Definitive Agreement. On May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell in a registered offering shares of its common stock, par value $0.00001 per share (the “Common Stock”), having an aggregate offering price of up to $6,150,000 from time to time through or to the Sales Agent (the “ATM Offering”). The…
Entry into a Material Definitive Agreement. On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd,…
Termination of a Material Definitive Agreement. The information set forth in
Entry into a Material Definitive Agreement. On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd,…
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Entry into a Material Definitive Agreement. On March 31, 2026, FibroBiologics, Inc. (the “Company”) commenced a best-efforts public offering (the “Offering”) of (i) 1,028,788 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), (ii) pre-funded warrants in lieu of Shares to purchase up to 1,243,940 shares of Common Stock (“Pre-Funded Warrants”), and (iii) warrants to purchase one share of its Common Stock for each Share of Common Stock and/or…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 4, 2026, the Compensation Committee of the Board of Directors of FibroBiologics, Inc. (the “Company”) approved a new annual base salary of $400,000, effective January 1, 2026, for Jason D. Davis, the Company’s Chief Financial Officer. Mr. Davis’ target amount as a percentage of base salary for annual non-equity incentive compensation remai…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 4, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its market value of listed securities (“MVLS”) had closed below the minimum $35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listin…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 1, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market un…
Entry into a Material Definitive Agreement. On December 14, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 5,227,275 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The p…
Unregistered Sales of Equity Securities. The disclosure set forth above in
Unregistered Sales of Equity Securities. The disclosure set forth above in
Entry into a Material Definitive Agreement. On November 24, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The p…
Unregistered Sales of Equity Securities. The disclosure set forth above in
Entry into a Material Definitive Agreement. On November 18, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single investor (the “Purchaser”), pursuant to which (i) the Company agreed to issue and sell to the Purchaser, in a registered direct offering (the “Registered Direct Offering”), 3,540,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”) and pre-funded warrant…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 4, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it does not meet the requirement in Nasdaq Listing Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35.0 million that is required for continued listing…
Unregistered Sales of Equity Securities. As previously disclosed, on December 20, 2024, FibroBiologics, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Islands exempt limited company (the “Investor”). Pursuant to the SEPA, the Company issued a convertible promissory note to the Investor in the principal amount of $5.0 million on each of December 20, 2024 (the "First Note"), December 30, 2024 (the “Second Note”), and June 16, 202…
of the Original Form 8-K is hereby supplemented as follows: The maximum number of shares of common stock of the Company that may be issued through the conversion of the $15.0 million aggregate principal amount of the Promissory Notes is 36,945,812 shares, assuming a conversion price of $0.406 per share, subject to anti-dilution adjustments. The maximum number of shares of common stock of the Company that may be issued through the Commitment Amount is 4,424,778 shares, assuming a purchase pric…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 1, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive trading days (the “Notice”), as requir…
Entry into a Material Definitive Agreement. Third Closing As previously disclosed, on December 20, 2024 (the “Effective Date”), FibroBiologics, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Islands exempt limited company (the “Investor”). Pursuant to the SEPA, among other things, the Investor agreed to advance to the Company, subject to the satisfaction of certain conditions as set forth therein, the principal amount of $15 mi…
Unregistered Sales of Equity Securities. On December 20, 2024, the first tranche of the Pre-Paid Advance was disbursed and the Company issued a convertible promissory note to the Investor in the principal amount of $5.0 million. On December 30, 2024, the second tranche of the Pre-Paid Advance was disbursed and the Company issued a convertible promissory note to the Investor in the principal amount of $5.0 million (the “Second Note”). On June 16, 2025, the third tranche of the Pre-Paid Advance…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth above in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”). Mr. Davis, age 53, served as Chief Financial Officer at Virax Biolabs, a biotechnology company, between March 2022 and June 2025. From December 2019 to…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.